Effects of Male-specific Antibodies on Sex Ratio

Sex Ratio Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02267252
• Other study ID #: Lab.Reprod.Biol.- Odense.01
• Status: Recruiting
• Start date: September 2014
• Est. completion date: June 2025

Study information

• Verified date: November 2023
• Source: Odense University Hospital
• Contact: Jens Fedder, MD, PhD
• Phone: +45 26820368
• Email: fedder[@]dadlnet.dk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Investigation of the ability of antibodies from vasectomized men in binding to Y-spermatozoa as a possible explanation of the lower sex ratio observed after microinsemination using epididymal sperm from vasectomized men.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

• Vasectomized men

Exclusion Criteria:

• Men who do not understand the study information

Related Conditions & MeSH terms

• Sex Ratio
• Sperm Antibodies

Intervention

Other:
• Antibody-sperm binding

Locations

Country	Name	City	State
Denmark	Fertility Clinic, Odense University Hospital	Odense

Sponsors (1)

Lead Sponsor	Collaborator
Odense University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Y/X sperm ratio after exposure to sperm-specific antibodies		Up to 28 months